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Background: Acquisition of mesenchymal phenotype by epithelial
cells by means of epithelial-mesenchymal transition (EMT) is con-
sidered as an early event in the multistep process of tumor metas-
tasis. Therefore, inhibition of EMT might be a rational strategy to
prevent metastasis.
Methods: Using the global gene expression profile from a cell
culture model of transforming growth factor- (TGF-)-induced
EMT, we identified potential EMT inhibitors. We used a publicly
available database (www.broad.mit.edu/cmap) comprising gene ex-
pression profiles obtained from multiple different cell lines in
response to various drugs to derive negative correlations to EMT
gene expression profile using Connectivity Map, a pattern matching
tool.
Results: Experimental validation of the identified compounds
showed rapamycin as a novel inhibitor of TGF- signaling along
with 17-AAG, a known modulator of TGF- pathway. Both of these
compounds completely blocked EMT and the associated migratory
and invasive phenotype. The other identified compound, LY294002,
demonstrated a selective inhibition of mesenchymal markers, cell
migration and invasion, without affecting the loss of E-cadherin
expression or Smad phosphorylation.
Conclusions: Our data reveal that rapamycin is a novel modulator
of TGF- signaling, and along with 17-AAG and LY294002, could
be used as therapeutic agent for inhibiting EMT. This study dem-
onstrates the potential of a systems approach in identifying novel
modulators of a complex biological process.
KeyWords: TGF-beta, Epithelial-mesenchymal transition, Connec-
tivity map, Lung cancer, mTOR, PI3K, HSP90.
(J Thorac Oncol. 2011;6: 1784–1792)
Metastasis is the major cause of mortality in cancer-related deaths. Hence, determining and targeting pre-
cise molecular mechanisms of metastasis is critical for a
successful prevention strategy. During metastasis, cancer
cells acquire the ability to invade surrounding tissue with
subsequent dissemination to secondary organs.1 The acquisi-
tion of migratory and invasive capability by otherwise sta-
tionary epithelial cells is associated with gain of mesenchy-
mal characteristics and concomitant loss of epithelial
phenotype, a phenomenon referred to as epithelial-mesenchy-
mal transition (EMT).2 EMT also confers resistance to anoi-
kis, evasion of immune surveillance, and in certain cases is
associated with stem cell-like properties of the resulting
mesenchymal cells, all of which may be required for a cancer
cell to successfully metastasize. Therefore, inhibition of EMT
might be a rational strategy to prevent metastasis.
The cytokine transforming growth factor- (TGF-)
plays a paradoxical role in cancer biology, whereby it acts as
a tumor suppressor in early stages and as a tumor promoter in
late stages of tumor progression. The tumor-promoting func-
tions of TGF- include induction of EMT in cancer cells.3–5
Depending on the cell type and context, TGF- induces EMT
by activation of multiple signaling pathways, both Smad-
dependent and Smad-independent, and cross talk with devel-
opmental pathways like WNT and Notch signaling.6–9 Given
the complex nature of EMT regulation, it is challenging to
identify critical regulatory molecules or pathways for target-
ing EMT.
System-wide profiling of molecular changes offers an
opportunity to understand the underlying mechanisms and
design strategies to perturb the system.10 Gene expression
profiling represents all the transcriptional alterations happen-
ing in a given disease state and time. Compounds that can
reverse some, if not all, of these changes might serve as
potential inhibitors of that particular disease state. A recently
developed pattern matching tool known as Connectivity Map
(C-Map) has demonstrated its utility in identifying potential
inhibitors using gene expression profiles of a given biological
state. The C-Map tool is built on a database comprised of 564
gene expression profiles derived from multiple cell lines after
treatment with 164 different compounds at different doses
(453 profiles or “instances”), along with 111 corresponding
controls.11 Using C-Map, one can derive negative correla-
tions between the gene expression perturbations of the bio-
logical state of interest and the perturbations of each drug
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instance in the database. The drugs whose instances are most
significantly correlated are ones that may serve as potential
inhibitors of that particular state; in this case it is EMT. Using
C-Map, we analyzed the global gene expression profile ob-
tained from TGF--induced EMT in the A549 lung adeno-
carcinoma cell line to identify potential inhibitors of EMT.
We identified known and new potential EMT inhibitors.
Validation of these compounds for EMT inhibition revealed
their novel mechanism of action and the potential of targeting
mammalian target of rapamycin (mTOR), HSP90, and PI3K
pathways for inhibiting EMT, tumor cell migration and
invasion.
EXPERIMENTAL PROCEDURES
EMT Experiment with Test Compounds
A549 (human lung adenocarcinoma) and H358 (human
bronchioalveolar carcinoma) cell lines were obtained from
the American Type Culture Collection (Manassas, VA) and
maintained in Roswell Park Memorial Institute 1640 medium
with supplemented with 10% fetal bovine serum, glutamine,
penicillin, and streptomycin at 37°C in 5% CO2. The authen-
tication of cell lines was not performed by authors. In all
experiments, cells at 40% to 50% confluency in complete
medium were serum starved for 24 hours and were treated
with TGF- (5 ng/ml) for 72 hours in the presence and
absence of compounds at indicated concentrations. Test com-
pounds were added to the cultures 30 minutes before TGF-
stimulation. After 72 hours, cells were either lysed for as-
sessing protein expression or trypsinized for replating in the
transwell chambers for assessing migration and invasion. The
conditioned media was collected for estimation of matrix
metallo proteases (MMPs). All the test compounds used in
this study were purchased from Tocris Biosciences, USA.
Gene Expression and C-Map Analysis
A549 lung-cancer cells were treated with 5 ng/ml of
TGF- and harvested at various time points in three separate
experiments, and the resulting RNA collected, assayed using
Affymetrix HG-U133_plus_2 arrays, and analyzed as previ-
ously described.12 We used probe set annotation from Af-
fymetrix web sites (version na30, dated November 13, 2009).
Using two-way analysis of variance models with terms for the
three experiments and nine time points, we selected probe
sets that gave p less than 0.001 for each time point compared
with the 0 hour control samples and also gave average
fold-differences of at least 1.5-fold. This data set and the p
values and fold-differences obtained are publicly available as
GEO series GSE17708.12 We formed the union of the se-
lected probe sets for the 0.5-, 1-, and 2-hour time points as a
representative list of early-responding genes, and the union of
4 and 8 hours as representative list of intermediate-respond-
ing genes. For the three early time points, this yielded 478
probe sets increased with TGF- and 244 decreased, of which
237 and 113, respectively, were also on the smaller Af-
fymetrix U133A (or similar HT_HG-U133A) arrays, which
are the arrays used to generate data on the effects of various
compounds by Lamb et al.13 in their work on “The Connec-
tivity Map.” For the union of 4 and 8 hours time points, we
obtained 1884 increased and 1254 decreased probe sets, of
which 1006 and 703 were on U133A arrays. The C-Map data
consist of 164 compounds tested on several cell lines (MCF7,
PC-3, HL-60, and SKMEL5), with a total of 453 treatments,
called instances, and 111 arrays of appropriate control treat-
ments (564 total arrays). We input our list of up and down
probe sets, given values of 1 and 1, into the software of
Zhang and Gant,14 which computes Cscores that are similar to
correlation coefficients between our values and the ranks of
the ratios of treatment to the average of controls for the
instances of Lamb et al. Negative Cscores indicate the com-
pound altered probe sets in an opposite-correlated way com-
pared with the differences we observed with TGF- treat-
ment. The software computes similar scores in 10,000
additional runs in which the probe set labels are randomly
permuted and computes two-sided permutation test p values
as the fraction of scores from permuted data sets with larger
absolute value than the one actually obtained for the instance.
To judge the significance of compounds, Cscores for the
instances of the compound are averaged to compute the
SetCscore for each compound, and this averaging is also
performed on the permuted data sets, and the software again
computes permutation test p values. With only 10,000 per-
muted data sets, these p values can be no smaller than 0.0001;
however, the means and standard deviations of the SetC-
scores from permutations are also reported, enabling us to
obtain a finer-grained test of significance by dividing the
SetCscore by this standard deviation and computing two-
sided tests by referring this standardized SetCscore to stan-
dard Normal (Gaussian) distributions. For p values of approx-
imately 0.0001 and larger the two methods agreed fairly well,
but for the largest SetCscores the p values from standardized
SetCscores were much smaller, as expected, and enabled us
to better judge the relative evidence in favor of the top-
scoring compounds.
Fluorescence Microscopy
Cells treated in 48-well tissue culture plates were fixed
in 4% formalin, blocked with 5% horse serum, permeabilized
with 0.3% Triton-X 100 and stained with FITC conjugated
E-cadherin antibody overnight at 4°C. Subsequently, cells
were washed with phosphate-buffered saline and stained
sequentially for F-actin with Rhodamine Phalloidin and for
nuclei with DAPI. Images were captured using a fluorescent
microscope (EVOSfl, Bothell, WA) at 20 magnification.
Images were processed by Adobe Photoshop (Adobe Systems
Inc., San Jose, CA).
Cell Migration and Invasion Assays
In vitro migration assays were performed as previously
described.15 Briefly, cells were seeded in the top chamber of
the 8.0 m pore size cell culture inserts that were either
coated or uncoated with matrigel for migration and invasion
assays, respectively. Then the inserts were placed in a 24-well
plate filled with Roswell Park Memorial Institute 1640 me-
dium with 5% fetal bovine serum. Cells that penetrated to the
underside surfaces of the inserts were fixed and stained with
the Diff-Quick (Fisher Scientific, Pittsburgh, PA) method
and were counted under the microscope. The mean of three
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high power fields for each condition run in triplicates was
calculated.
Western Blot
Samples containing 20 g of total protein were elec-
trophoresed on SDS–polyacrylamide gels and transferred
onto a polyvinyldifluoride membrane by electroblotting.
Membranes were probed with primary antibodies with over-
night incubation at 4°C, followed by horseradish peroxidase–
conjugated secondary antibodies. Finally, the immunoblots
were visualized by using ECL reagents.
Smad Transcriptional Activity
Effect of test compounds on Smad transcriptional ac-
tivity was determined in A549-SBE (Smad Binding Ele-
ments)-Luc cells as previously described.15 Briefly, cells
were serum starved overnight and treated with TGF- (5
ng/ml) in presence and absence of compounds pretreatment.
After 4 hours, luciferase activity was measured using the
steady-glo luciferase kit (from Promega, USA) as per the
manufacturer’s instructions. Luciferase counts were normal-
ized to the total protein concentrations in the respective
samples.
Statistical Analysis
Data are represented as mean  standard deviations
and were analyzed with the Prism version 4.0 statistical
program (GraphPad Software, San Diego, CA). Groups were
compared using one-way analysis of variance or student
t test. Differences were considered significant if p less than
0.05.
RESULTS
C-Map Analysis using Early Gene Expression
Changes during EMT-Identified Potential
Inhibitors of EMT
Stimulation of cells with TGF- induces activation and
nuclear translocation of transcription factors Smad2 and
Smad3.16 This results in the subsequent robust transcriptional
regulation of the target genes. These transcriptional changes
are critical for the regulation of TGF--induced complex
biological responses including EMT.16 Reversal of these
transcriptional changes may be critical for inhibiting EMT.
Therefore, to identify inhibitors of EMT, we derived a list of
TGF--responding (increased and decrease) probe sets in
EMT, from the union of three time points (0.5, 1, and 2 hours)
from a time course gene expression analysis of TGF--
induced EMT in the A549 lung adenocarcinoma cell line.12
Using the C-Map tool, we computed connectivity scores
(Cscores) between this EMT profile and the 453 instances in
Lamb et al.13 data base from 164 compounds. Cscores are
similar to correlation coefficients, and a negative Cscore
indicates that the compound from which that instance is
derived potentially reverses the gene expression changes in
the input profile, which in this case was EMT. The Cscores
for the instances were averaged to obtain SetCscores for each
compound, and we standardized these by dividing the stan-
dard deviation of the SetCscores for the same compound,
obtained from 10,000 data sets in which the probe set labels
were randomly permuted. We identified 49 negatively corre-
lated compounds with p less than 0.01, of which 30 gave p
less than 0.0001. To focus on the most reliable findings, we
reduced these 30 candidates to 21 compounds that had at least
two instances, which are shown in Table 1. Because a total of
95 compounds had at least two instances, we expect only
approximately 0.01 (0.000195) false-positive compounds
using this selection criterion. Compounds identified include
inhibitors of HSP90, PI3K, mTOR, cycloxygenase, prosta-
glandin synthetase, DNA gyrase, Rho-Kinase, Calcineurin,
purine synthesis, -estradiol, and aromatase. Interestingly,
for all 21 compounds, either the compounds themselves or
the primary pathways that the compounds are known to
inhibit were implicated in cancer (Table 1). This includes the
unanticipated, antipsychotic compounds Chlorpromazine and
Clozapine, which have also shown to inhibit cancer cell
growth.27,39 Complete analysis and the Cscores derived for
all the instances are presented in Supplementary Table 1
(http://links.lww.com/JTO/A128). Similar analysis with
the gene profile derived from the union of 4- and 8-hour
time points also largely identified the same compounds
(Supplementary Table 1, http://links.lww.com/JTO/A128)
with compound scores for two temporal profiles being
highly correlated (r 0.90 for 95 compounds, p 1 1034).
Experimental Validation of Compounds
Identified by the C-Map Analysis
EMT is characterized by loss of epithelial markers
(E-cadherin) and gain of mesenchymal markers (N-cadherin,
Vimentin) resulting in the acquisition of migratory and inva-
sive phenotype. Hence, to test the ability of the compounds
identified by C-Map analysis, to inhibit EMT, we assessed
their effects on biochemical markers and functional attributes
of EMT in two different cell culture models, A549 and H358.
A549 Cells were stimulated with TGF- (5 ng/ml) in the
presence and absence of test compounds at indicated concen-
trations and assessed stress-fiber formation, expression of
epithelial and mesenchymal markers by immunofluorescence
microscopy and western immunoblotting (Figures 1A, B).
Consistent with EMT, 72 hours TGF- treatment signifi-
cantly suppressed the E-cadherin expression compared with
the untreated controls (Figures 1A, B). However, the presence
of rapamycin (Sirolimus, mTOR inhibitor) or 17-AAG
(HSP90 inhibitor) completely reversed TGF--induced sup-
pression of E-cadherin expression, at all concentrations tested
(Figures 1A, B). Further, both the compounds also blocked
basal and TGF--induced up-regulation of mesenchymal
marker N-cadherin. Treatment of Rapamycin and 17-AAG
alone induced a slight increase in the basal vimentin levels in
the control cells, but it was not statistically significant (Sup-
plementary Figure 1, http://links.lww.com/JTO/A129). Al-
though rapamycin had no effect, 17-AAG completely abro-
gated the TGF--induced vimentin expression (Figure 1B).
Interestingly, LY294002 had no effect on TGF--induced
E-cadherin suppression (Figures 1A, B), but attenuated both
the basal and TGF--induced up-regulation of N-cadherin
and vimentin, suggesting a selective effect on mesenchymal
phenotype (Figure 1B). Consistent with their effect on mes-
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enchymal phenotype, all the three compounds inhibited TGF-
-induced change in morphology and stress fiber formation in
A549 cells (Figure 1A). Reflecting their effect on epithelial
and mesenchymal markers, rapamycin and 17-AAG inhibited
EMT-induced cellular migration and invasion in A549 cells
(Figure 2). These two compounds also blocked concomitant
secretion of MMP2 and MMP9 during EMT (Data not
shown). Interestingly, LY294002, which only inhibited
mesenchymal markers, also inhibited EMT-induced cellu-
lar migration, invasion (Figure 2A) and MMP secretion
(Data not shown). All the above three compounds, dem-
onstrated similar effects on expression of E-cadherin and
vimentin (Figure 1C), and cellular invasion (Figure 2)
during TGF--induced EMT in H358 cells, another non-
small cell lung cancer cell line. This demonstrates that the
observed effects of these compounds are not specific to a
single cell line (Supplementary Figure 1 and Supplemen-
tary Table 2, http://links.lww.com/JTO/A128).
From the list of compounds identified, we also assessed
the effect of acetylsalicyclic acid and novobiocin on TGF--
induced EMT. At the concentrations tested, both these com-
pounds showed no significant effects on either biochemical or
functional markers (migration and invasion) of EMT (data
not shown). However, we have not ruled out the effect of
these two compounds on the other functional phenotypes
conferred by EMT, including growth inhibition, resistance to
apoptosis, evasion of immune surveillance and, in certain
cases, stem cell-like properties.2,40
Effect of Rapamycin, 17-AAG, and LY294002
on Smad Phosphorylation and Transcriptional
Activation
TGF- induces robust phosphorylation of Smad 2 and
3, by TGF--receptor-I kinase, within 1 hour and persists
beyond 4 hours. Both Smad-dependent and independent sig-
naling pathways were implicated in TGF--induced EMT.8
However, in different cells, we and others41 have shown that
activation of Smad3 is indispensible for TGF--induced
EMT, including in A549 cells.42 We tested the above three
compounds for their potential effects on TGF--induced
Smad phosphorylation. A549 cells were stimulated with
TGF- for 1 hour in the presence and absence of LY-294002
or rapamycin or 17-AAG at indicated concentrations and
assessed for Smad2 and Smad3 phosphorylation by western
immuno-blotting. All three compounds had no effect on
Smad2 or Smad3 phosphorylation after 1 hour of TGF-
TABLE 1. Top Scoring Compounds in C-Map Analysis: The 21 Compounds with Probe Set alterations Negatively Correlated
to Early (0.5, 1, and 2 h) Alterations Observed with TGF- Treatment are Given
Compound
Set
Size
Standardized SetCscore
(0.5, 1, 2 h)
p Value from
Standardized
SetCscore (Z-Score) Mode of Action
Relevance in
Cancer (Reference)
17-Allylamino-geldanamycin 18 7.73 1.07E  14 HSP90 inhibitor 17, 18
LY294002 17 5.91 3.41E  09 PI3K inhibitor 19, 20
Sirolimus (Rapamycin) 10 4.72 2.36E  06 mTOR inhibitor 19, 21
Geldanamycin 6 5.33 1.01E  07 HSP90 inhibitor 17, 18
Novobiocin 6 4.17 3.10E  05 DNA Gyrase inhibitor 22, 23
Nordihydroguaiaretic acid 5 5.20 1.96E  07 Cyclooxygenase inhibitor 24, 25
Staurosporine 4 5.42 5.87E  08 Protein Kinase C inhibitor 26
Chlorpromazine 4 4.84 1.31E  06 Dopamine and seretonin
receptor antagonist
27
SC-58125 4 4.01 5.96E  05 Cyclooxygenase inhibitor 28
LM-1685 3 5.50 3.81E  08 Cyclooxygenease
inhibitor
25, 29
Acetylsalicylic acid 3 5.36 8.46E  08 Cyclooxygenase inhibitor 25, 30
17-dimethylamino-geldanamycin 2 6.39 1.67E  10 HSP90 inhibitor 17, 18
Cyclosporin 2 5.41 6.40E  08 Calcineurin inhibitor 31, 32
Fasudil 2 5.23 1.71E  07 Rho-kinase inhibitor 33
Mercaptopurine 2 5.17 2.40E  07 Purine synthesis inhibitor 34
Oxaprozin 2 5.16 2.52E  07 Prostaglandin synthetase
inhibitor
35
Diclofenac 2 4.85 1.26E  06 Cyclooxygenase inhibitor 25
4,5-Dianilinophthalimide 2 4.68 2.88E  06 Multikinase inhibitor 36
NU-1025 2 4.62 3.77E  06 PARP inhibitor 37
Butein 2 4.41 1.03E  05 Aromatase inhibitor 38
Clozapine 2 3.91 9.05E  05 Dopamine and serotonin
receptor antagonist
39
Each compound was represented by at least two instances (SetSize) and gave p  0.0001 for a Z-score test of the average Cscores for all the instances of the compound
(SetCscores). The p values are two-sided tests based on the standardized SetCscore, which were the SetCscores divided by the standard deviation of this score computed from 10,000
random permutations of the probe set labels. Detailed results for all 164 compounds are given in Supplementary Table.
C-map, Connectivity Map; mTOR, mammalian target of rapamycin.
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stimulation (Figure 3A). This demonstrates that none of these
three compounds have any nonspecific effect on the TGF--
receptor-I kinase.
In a recent study, HSP90 was shown to be critical for
the stability of TGF- receptors, after stimulation with
TGF-, for a sustained Smad phosphorylation. As a result,
inhibitors of HSP90 had no effect on immediate Smad phos-
phorylation within an hour, but blocked sustained Smad
phosphorylation as they triggered slow degradation of TGF-
-receptors.43 Consistent with these findings we observed a
FIGURE 1. Effect of rapamycin, 17-AAG and LY 294002 on Epithelial and mesenchymal markers during transforming growth
factor- (TGF-) induced epithelial-mesenchymal transition (EMT). A549 or H358 cells were serum starved for 24 hours, pre-
treated with inhibitors and stimulated with or without TGF- (5 ng/ml). After 72 hours, (A) E-cadherin and stress fibers (F-ac-
tin by Phalloidin staining) were assessed in A549 cells by immunofluorescence (scale bar 100 m), (B) epithelial (E-cadherin)
and mesenchymal (N-cadherin, vimentin) markers were assessed in A549 cells, (C) epithelial (E-cadherin) and mesenchymal
(vimentin) markers in H358 cells were assessed by western immunoblotting. Quantitation of western immunoblotting data
from three independent experiments was done by ImageJ software and presented in Supplementary Figure S1.
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total inhibition of Smad phosphorylation after 4 hours of
TGF- stimulation (Figure 3B). Interestingly, in contrast to
its effect at 1 hour time point, rapamycin also blocked Smad
phosphorylation at 4 hours after TGF- stimulation (Figure
3B), whereas LY294002 had no effect on Smad phosphory-
lation at either time points (Figures 3A, B).
Effect of Rapamycin, 17-AAG, and LY294002
on Smad Transcriptional Activity
Following TGF- stimulation, phosphorylated Smad 2
or 3 translocate into the nucleus as Smad 2/4 or Smad 3/4
heterodimers, bind to the SBE in the promoters of their target
genes and trigger gene transcription. To determine whether
these compounds had any effect on TGF--induced Smad
transcriptional activity, we tested the effect of these com-
pounds in the presence and absence of TGF- in A549 cells
stably transfected with a Lentiviral based SBE-Luciferase
reporter plasmid. Consistent with the inhibition of Smad
phosphorylation, both 17-AAG and rapamycin significantly
inhibited the TGF- induced Smad transcriptional activity
(Figures 4A, B). Surprisingly, although LY294002 had no
effect on smad phosphorylation, it inhibited the TGF--
induced transcriptional activation (Figure 4C).
DISCUSSION
Recently, several groups successfully identified and
validated potential modulators of different biological pro-
cesses by analyzing the gene expression profiles using C-Map
approach.11,44–46 C-Map analysis does not require previous
FIGURE 2. Effect of rapamycin, 17-AAG and LY 294002 on migration and invasion during transforming growth factor-
(TGF-) induced epithelial-mesenchymal transition (EMT): A549 or H358 cells were serum starved for 24 hours, stimulated
with TGF- (5 ng/ml) in the presence or absence of inhibitors at indicated concentrations. After 72 hours, cells were
trypsinized and plated in uncoated or matrigel-coated transwell chambers to assess cellular migration and invasion, respec-
tively. Error bars represent the standard deviation (SD) from three independent replicates. *Statistically significant (p  0.05)
difference when compared with TGF- treated cells.
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knowledge of the molecules or pathways involved in a
biological process. Instead, by simply using the pattern of
gene expression alterations under study, compounds that can
potentially reverse those alterations and therefore can serve as
potential inhibitors of the process can be identified. Using
this approach, we identified 21 compounds with various
mechanisms of action as potential inhibitors of EMT and
validated their affects in two independent TGF- induced
EMT models.
Experimental validation of hits from C-Map analysis
identified rapamycin as a novel inhibitor of TGF- signaling
and a potent inhibitor of EMT. Rapamycin in complex with
FKBP12 interacts with mTOR and inhibits its activity in the
mTOR C1 complex.47 mTOR activity is increased in many
tumors, including lung cancer48; inhibition of mTOR function
through rapamycin analogues is considered as promising
therapeutic strategy. Earlier reports have suggested that acti-
vation of mTOR is a Smad-independent TGF- pathway that
regulates protein synthesis, complementing the Smad-medi-
ated transcriptional regulation.49 Studies with NMuMG
mouse mammary epithelial cells and HaCat human keratin-
ocytes showed no effect of rapamycin on TGF--induced
EMT; however, rapamycin blocked EMT-associated increase
in cell size and invasion in these cells.49 In contrast, we
observed a potent inhibition of TGF--induced EMT by
rapamycin in both A549 and H358 models of EMT. The
effect of rapamycin on EMT was evident at the level of both
biochemical markers (preventing the loss of E-cadherin and
gain of N-cadherin proteins) and at the resulting functional
phenotype (inhibition of migration and invasion). This dis-
crepancy might be indicative of a potential difference in
TGF- signaling between malignant (A549) and nonmalig-
nant (NMuMG and HaCat) cells.
The most surprising observation was the effect of
rapamycin on TGF--induced Smad phosphorylation. Rapa-
mycin significantly inhibited phosphorylation of Smad2 and
Smad3 at 4 hours, but not at 1 hour, after TGF- stimulation.
This clearly indicates that the effect of rapamycin on Smad
phosphorylation is not due to a nonspecific or off-target effect
on TGF- receptor-I kinase. The HSP90 inhibitor 17-AAG
demonstrated similar kinetics in inhibiting Smad phosphory-
lation (Figures 3A, B). This is consistent with the recent
finding that HSP90 is critical for the stability of TGF-
receptors and required longer duration of drug treatment to
observe significant degradation of TGF- receptors.43 Ac-
cordingly, 17-AAG was also a potent inhibitor of EMT in this
study in both cell types tested. Given the similarity between
the effects of rapamycin and 17-AAG, it may be important to
investigate the role of rapamycin and potentially mTOR in
regulating the stability of TGF- receptors, particularly in
cancer cells. As opposed to our observations, earlier studies
have reported potentiation of TGF- signaling with rapamy-
cin.50 FKBP12, the protein to which rapamycin binds, inter-
acts with TGFRI to inhibit activation of Smads.50,51 It was
suggested that presence of rapamycin sequesters FKBP12
from TGFRI to potentiate TGF- signaling.52 These obser-
vations were primarily made in nonmalignant epithelial cells
and predominantly from the NMuMG mouse mammary epi-
thelial cell line. It would be interesting to investigate whether
the FKBP12 pathway is still functional in cancer cells and, if
FIGURE 3. Effect of rapamycin, 17-AAG and
LY 294002 on transforming growth factor-
(TGF-) induced Smad phosphorylation: A549
cells were serum starved for 24 hours, stimu-
lated with TGF- (5 ng/ml) in the presence or
absence of inhibitors for 1 (A) or 4 (B) hours.
Cell lysates were assessed for phospho-Smad 2
and 3 and total Smad 2 and 3 protein levels by
western immunoblotting.
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it is, then how rapamycin is modulating TGF- signaling. In
contrast to rapamycin and 17-AAG, LY294002 had no effect
on Smad phosphorylation. Interestingly, LY294002 did sig-
nificantly inhibit TGF--induced Smad transcriptional activ-
ity, suggesting a role for the PI3K pathway in the transcrip-
tional regulation of TGF- signaling.
Earlier reports showed cross-talk between PI3K and
mTOR pathways where inhibition of one pathway modulates
the other, depending on the cell type and the context. Hence,
it was expected that inhibition of PI3K or mTOR may result
in similar effects. On the contrary, we observed that rapamy-
cin attenuated both E-cadherin loss and N-cadherin gain,
whereas LY294002 selectively inhibited EMT-induced
N-cadherin and vimentin expression without affecting the
loss of E-cadherin. This suggests that both these compounds
have effects that are independent of the cross-talk between
them, such as modulation of TGF- signaling by rapamycin.
However, both compounds equally blocked EMT-induced
migration, invasion and MMP secretion that strongly suggests a
role for both cross-talk dependent and independent pathways.
In addition to these three compounds, we also assessed
the effect of acetylsalicyclic acid and novobiocin on TGF--
induced EMT. At the concentrations tested, both these com-
pounds showed no significant effects on either biochemical or
functional markers (migration and invasion) of EMT (data
not shown). Apart from migratory and invasive phenotype,
EMT is known to confer other functional phenotypes to
cancer cells, including growth inhibition, resistance to apo-
ptosis, evasion of immune surveillance and, in certain cases,
stem cell-like properties.2,40 Therefore, it is possible that
the compounds that showed no effect on the markers we
tested may still affect the other functional phenotypes
described earlier to justify their identification as potential
EMT inhibitors.
In summary, despite the prevalent notion that rapamy-
cin either potentiates TGF- signaling50 or has no effect on
EMT,49 we identified rapamycin as a candidate inhibitor of
TGF- signaling and EMT. Also, in contrast to previous
reports,53 we identified LY294002 as a selective inhibitor of
mesenchymal phenotype during EMT. In addition, 17-AAG
was identified as a potent EMT inhibitor which was consis-
tent with the role of HSP90 in the stability of TGF- recep-
tors.43 Collectively, these results demonstrate the need for
such system-wide approaches54 to look beyond the bias of
previous information for gaining new insights.
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